Orexo announces addendum to prospectus made public

Orexo announces addendum to prospectus made public

 

Read more about Orexo Rights Issue at:

http://www.orexo.com/en/Investor-Relations/Rights-issue---Important-Info
rmation/ (http://www.orexo.com/en/Investor-Relations/Rights-issue---Impo
rtant-Information/)

For further information, contact:
Anders Lundström, President and CEO of Orexo
Tel: +46 (0)70-667 22 66
E-mail: anders.lundstrom@orexo.com (anders.lundstrom@orexo.com)

 

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. The company has four commercialized products,
several projects developed in partnership as well as three proprietary
development programs. Orexo's registered products are Abstral® for the
treatment of break through cancer pain, sold by Kyowa Hakko
Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill
Edluar™, sold by Meda in the USA, as well as two products for the
diagnosis of Helicobacter pylori which are being marketed by the
subsidiary Kibion. More information can be found at
www.orexo.com (http://www.orexo.com/).

 

Note
Orexo AB (publ) discloses the information provided in this press release
pursuant to the Securities Markets Act. The information was provided for
public release on 15 June 2011 at 08.30 a.m. CET. This press release has
been prepared in both Swedish and English. In the event of any
discrepancy in the content of the two versions, the Swedish version
shall take precedence.

 

This press release does not constitute an offer of any securities of
Orexo. The rights offering is not directed to shareholders or other
investors domiciled in the United States, Canada, Japan or Australia, or
in any other country where participation in the issue would require
additional prospectuses, registration or other measures other than those
pursuant to Swedish law or would conflict with regulations in such
country. No shares, interim shares, subscription rights or other
securities issued by Orexo have been or will be registered in accordance
with the United States Securities Act of 1933, or in accordance with any
securities legislation in any state of the United States or any province
in Canada. Accordingly, no new shares, interim shares, subscription
rights or other securities issued by Orexo may be transferred or offered
for sale in the United States or Canada, other than in such exceptional
cases that do not require registration. The rights offering is directed
only at (i) persons who are outside the United Kingdom; or (ii)
investment professionals falling within Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 (as
amended); or (iii) persons to whom it can otherwise lawfully be directed
at.